Business Wire

Cloud Service Provider Bulutistan Selects Inspur Information to Upgrade Its Cloud Infrastructure

26.1.2022 09:04:00 CET | Business Wire | Press Release

Share

Inspur Information, a leading IT infrastructure solutions provider, today announced it was selected by Bulutistan, the leading cloud service provider in Turkey and a top 5 provider in the EMEA region, to upgrade the company’s cloud infrastructure. Bulutistan faces rapid growth in its public cloud services that cannot be met by traditional cloud computing architecture. Inspur Information’s hyper-converged solution based on Inspur’s NF5280M5 server provides the extreme scalability Bulutistan requires in addition to a 30% reduction in operational costs.

The three-tier architecture of traditional data centers (computing, storage, and network) is stable and reliable, but it is difficult to expand and requires complex equipment and that is time consuming and difficult to manage. It is not suitable for the next-generation data center cloudification that Bulutistan requires. Instead, the company needed a pooled IT infrastructure platform with maximum capacity and scalability that is also efficient, easy to adjust and manage, and highly stable.

Understanding Bulutistan’s requirements for extreme scalability, flexibility, and stability, Inspur went through an extensive testing process and identified Nutanix's distributed storage software as the most effective way to integrate computing and storage. The Inspur hyper-converged solution and NF5280M5 server paired with Nutanix software would allow Bulutistan to upgrade to a customized cloud server platform with full-stack management analysis that is flexible and allows for unlimited expansion as an on-premises integrated solution. This logically simplified architecture is the key to why Bulutistan selected Inspur to upgrade its cloud infrastructure.

The Inspur one-click database management solution supports multiple file storage services and greatly simplifies system management. The hyper-converged architecture with distributed single-node management achieves excellent performance with high stability and advanced recovery capabilities. The solution can flexibly allocate computing resources across clusters and units without reconfiguring the physical network or external storage. Computing virtualization is achieved through VMware, and network virtualization is achieved through NFV to provide simple and intuitive configuration management tools for allocating resources. Server computing and storage resources can be adjusted according to actual needs for true on-demand and dynamic resource allocation.

The system greatly simplifies management complexity and improves operation and maintenance efficiency, resulting in a 30% reduction in costs. Modular construction with on-demand linear and rapid expansion reduces deployment times to 1/6th of what is typically expected. A highly scalable network interface is provided, further simplifying deployment and reducing operating costs.

This integration reduces operating costs while providing the same data reliability and availability of traditional architectures. Inspur Information offers a complete solution for a virtualization platform, including high-availability storage design, data security, and management. The hyper-converged solution developed for Bulutistan integrates a variety of analysis technologies, and creates a complete pooled IT platform by combining hyper-convergence, VMware virtualization, NFV, and storage.

About Inspur Information

Inspur Information is a leading provider of data center infrastructure, cloud computing, and AI solutions, and is a top two server manufacturer worldwide. Through engineering and innovation, Inspur Information delivers cutting-edge computing hardware design and extensive product offerings to address important technology segments such as open computing, cloud data centers, AI, and deep learning. Performance-optimized and purpose-built, our world-class solutions empower customers to tackle real-world challenges and custom workloads. To learn more, please go to https://www.inspur.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Fiona Liu
Inspur Information
liuxuan01@inspur.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye